Previous 10 | Next 10 |
2023-03-09 05:59:46 ET Summary Rigel Pharma has 2 FDA-approved drugs: Tavalisse for chronic immune thrombocytopenia (ITP) and Rezlidhia for relapsed or refractory AML with susceptible IDH1 mutation. In Q4 2022, Tavalisse revenue slightly rose, yet its utilization in ITP remains re...
2023-03-08 11:54:50 ET During Wednesday's midday trading, the major U.S. equity indexes were mixed, as Wall Street tried to recover following hawkish comments by Federal Reserve Chairman Jerome Powell the day before. Looking at the individual stocks, Korn Ferry ( NYSE: KFY )...
2023-03-08 10:44:00 ET As savvy investors know, penny stocks can offer high returns if chosen wisely. These stocks, which trade for less than $5 per share, often represent small companies with high growth potential. But they also carry high risks due to their volatility and low liquidity. T...
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
2023-03-07 23:45:19 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Conference Call March 7, 2023 04:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Comm...
2023-03-07 20:46:05 ET The following slide deck was published by Rigel Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Rigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-07 16:48:12 ET Q4 2022 beats on the top and bottom lines has propelled Rigel Pharmaceuticals ( NASDAQ: RIGL ) 19% higher in post-market trading. The beats were significant. For example, on the bottom line, Q4 non-GAAP EPS of $0.01 beat by $0.12 . In the...
2023-03-07 16:02:43 ET Rigel Pharmaceuticals press release ( NASDAQ: RIGL ): FY GAAP EPS of $0.34 beats by $0.80 . Revenue of $120.24M beats by $27.04M . For further details see: Rigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M ...
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update PR Newswire Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA ™ net product...
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that i...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...